Protocol Ledger

NCT06095583 · Phase III · RECRUITING

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventional Phase III clinical trial protocol NCT06095583 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-15 Enrollment: 756 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06095583
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)756 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06095583
Protocol FieldVerified Registry Value
NCT IdentifierNCT06095583
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment756 participants (ESTIMATED)
Registered Start Date2023-11-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI